Tags

Type your tag names separated by a space and hit enter

Outcomes after differential use of drug-eluting stents in diabetic patients: 1-year results from the DES.DE (Drug-Eluting Stent.DEutschland) registry.
Catheter Cardiovasc Interv. 2010 Jul 01; 76(1):50-7.CC

Abstract

OBJECTIVES

The prospective multicenter German DES.DE registry provides real world data to evaluate the therapeutic principle of two different drug-eluting stents (DES) [Sirolimus- (SES) and Paclitaxel-eluting stent (PES)] in the context of the German Health System.

BACKGROUND

Differential DES have been effective in randomized trials, but their difference in safety and efficacy in diabetic patients has not been well studied.

METHODS

Baseline, predefined procedural as well as clinical in-hospital and follow-up events were recorded for all 1,526 diabetic patients. The composite of death, myocardial infarction (MI), and stroke defined as major adverse cardiac and cerebrovascular events (MACCE) and target vessel revascularization (TVR) were defined as primary endpoints.

RESULTS

Between October 2005 and October 2006, 1,526 diabetic patients, 34.2% of them being insulin-dependent, were enrolled (SES: n = 612; PES: n = 914) at 98 DES.DE sites. Overall, one third of patients were admitted with acute coronary syndrome (ACS) and 70% had multivessel-disease reflecting a real world scenario. With similar baseline clinical and descriptive morphology of coronary artery disease (CAD) in both DES groups, there were no statistical differences in 1-year follow-up with respect to rates of overall mortality (5.8% vs. 5.4%), TVR (12.0% vs. 11.3%), overall stent thrombosis (5.6% vs. 4.6%) and MACCE (11.4% vs. 10.3%) between both DES.

CONCLUSION

The data collected in DES.DE revealed no differences in clinical outcomes within 1 year between SES and PES in diabetic patients in a "real-world" setting.

Authors+Show Affiliations

Department of Cardiology, University Hospital Rostock, Rostock School of Medicine, Ernst-Heydemann-Strasse 6, Rostock, Germany.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study

Language

eng

PubMed ID

20578192

Citation

Akin, Ibrahim, et al. "Outcomes After Differential Use of Drug-eluting Stents in Diabetic Patients: 1-year Results From the DES.DE (Drug-Eluting Stent.DEutschland) Registry." Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions, vol. 76, no. 1, 2010, pp. 50-7.
Akin I, Bufe A, Eckardt L, et al. Outcomes after differential use of drug-eluting stents in diabetic patients: 1-year results from the DES.DE (Drug-Eluting Stent.DEutschland) registry. Catheter Cardiovasc Interv. 2010;76(1):50-7.
Akin, I., Bufe, A., Eckardt, L., Reinecke, H., Richardt, G., Kuck, K. H., Senges, J., Schneider, S., & Nienaber, C. A. (2010). Outcomes after differential use of drug-eluting stents in diabetic patients: 1-year results from the DES.DE (Drug-Eluting Stent.DEutschland) registry. Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions, 76(1), 50-7. https://doi.org/10.1002/ccd.22450
Akin I, et al. Outcomes After Differential Use of Drug-eluting Stents in Diabetic Patients: 1-year Results From the DES.DE (Drug-Eluting Stent.DEutschland) Registry. Catheter Cardiovasc Interv. 2010 Jul 1;76(1):50-7. PubMed PMID: 20578192.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Outcomes after differential use of drug-eluting stents in diabetic patients: 1-year results from the DES.DE (Drug-Eluting Stent.DEutschland) registry. AU - Akin,Ibrahim, AU - Bufe,Alexander, AU - Eckardt,Lars, AU - Reinecke,Holger, AU - Richardt,Gert, AU - Kuck,Karl-Heinz, AU - Senges,Jochen, AU - Schneider,Steffen, AU - Nienaber,Christoph A, AU - ,, PY - 2010/6/26/entrez PY - 2010/6/26/pubmed PY - 2010/10/16/medline SP - 50 EP - 7 JF - Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions JO - Catheter Cardiovasc Interv VL - 76 IS - 1 N2 - OBJECTIVES: The prospective multicenter German DES.DE registry provides real world data to evaluate the therapeutic principle of two different drug-eluting stents (DES) [Sirolimus- (SES) and Paclitaxel-eluting stent (PES)] in the context of the German Health System. BACKGROUND: Differential DES have been effective in randomized trials, but their difference in safety and efficacy in diabetic patients has not been well studied. METHODS: Baseline, predefined procedural as well as clinical in-hospital and follow-up events were recorded for all 1,526 diabetic patients. The composite of death, myocardial infarction (MI), and stroke defined as major adverse cardiac and cerebrovascular events (MACCE) and target vessel revascularization (TVR) were defined as primary endpoints. RESULTS: Between October 2005 and October 2006, 1,526 diabetic patients, 34.2% of them being insulin-dependent, were enrolled (SES: n = 612; PES: n = 914) at 98 DES.DE sites. Overall, one third of patients were admitted with acute coronary syndrome (ACS) and 70% had multivessel-disease reflecting a real world scenario. With similar baseline clinical and descriptive morphology of coronary artery disease (CAD) in both DES groups, there were no statistical differences in 1-year follow-up with respect to rates of overall mortality (5.8% vs. 5.4%), TVR (12.0% vs. 11.3%), overall stent thrombosis (5.6% vs. 4.6%) and MACCE (11.4% vs. 10.3%) between both DES. CONCLUSION: The data collected in DES.DE revealed no differences in clinical outcomes within 1 year between SES and PES in diabetic patients in a "real-world" setting. SN - 1522-726X UR - https://www.unboundmedicine.com/medline/citation/20578192/Outcomes_after_differential_use_of_drug_eluting_stents_in_diabetic_patients:_1_year_results_from_the_DES_DE__Drug_Eluting_Stent_DEutschland__registry_ L2 - https://doi.org/10.1002/ccd.22450 DB - PRIME DP - Unbound Medicine ER -